Last Updated: 12/01/08
Toby T. Hecht, Ph.D., Acting Associate Director
Dr. Toby T. Hecht earned a Ph.D. in microbiology and immunology from the Albert Einstein College of Medicine. She did her post-doctoral research at Yale University before coming to the NIH where, among other accomplishments, she and her collaborators created a unique Hodgkin’s lymphoma-specific monoclonal antibody that was used in both imaging and therapy trials at the NIH Clinical Center and at the Beth Israel Deaconess Medical Center. Dr. Hecht has worked for almost 30 years at the NIH, 21 of which were spent at the NCI in programmatic activities and biological agent development. She has also guided many projects (from conception to testing in the clinic) through the NCI Rapid Access to Intervention Development (RAID) program and the Drug Development Group program; some of the agents have been licensed by pharmaceutical companies and have reached the marketplace. This year Dr. Hecht was chosen to oversee the transition of the SPORE program from the Office of the NCI Director to the Division of Cancer Treatment and Diagnosis in order to fully integrate the SPORE program into the translational science activities of the NCI.
